Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) insider Mark E. Dmytruk sold 47,806 shares of Ginkgo Bioworks stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $0.84, for a total transaction of $40,157.04. Following the completion of the sale, the insider now directly owns 925,400 shares of the company's stock, valued at approximately $777,336. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Ginkgo Bioworks Stock Performance
Shares of NYSE:DNA opened at $0.99 on Tuesday. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $0.74 and a 52-week high of $2.55. The company has a market cap of $2.13 billion, a P/E ratio of -2.10 and a beta of 1.42. The stock's 50-day moving average is $1.08 and its 200-day moving average is $1.31.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its earnings results on Thursday, February 29th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The business had revenue of $34.76 million during the quarter, compared to analyst estimates of $40.37 million. During the same period last year, the business earned ($0.04) EPS. The business's quarterly revenue was down 64.6% compared to the same quarter last year. As a group, equities analysts predict that Ginkgo Bioworks Holdings, Inc. will post -0.32 EPS for the current year.
Analyst Ratings Changes
[URGENT] DO NOT Touch These AI Stocks!
From Weiss Ratings | Ad
Artificial intelligence stocks are carrying the market.
One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap.
But is this AI rally over?
Click here for our #1 AI Stock for 2024 and Beyond
A number of brokerages have weighed in on DNA. The Goldman Sachs Group reduced their price target on Ginkgo Bioworks from $1.25 to $1.10 and set a "sell" rating for the company in a research report on Monday, January 22nd. TD Cowen decreased their target price on Ginkgo Bioworks from $7.00 to $3.00 and set an "outperform" rating for the company in a research report on Friday, March 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Ginkgo Bioworks presently has an average rating of "Hold" and a consensus price target of $2.20.
View Our Latest Research Report on DNA
Hedge Funds Weigh In On Ginkgo Bioworks
Several large investors have recently bought and sold shares of DNA. Spire Wealth Management bought a new position in shares of Ginkgo Bioworks during the 4th quarter worth about $25,000. First Trust Direct Indexing L.P. bought a new position in Ginkgo Bioworks during the first quarter valued at about $35,000. Prime Capital Investment Advisors LLC acquired a new position in Ginkgo Bioworks in the 4th quarter valued at approximately $37,000. Smith Salley & Associates lifted its position in shares of Ginkgo Bioworks by 100.0% in the 4th quarter. Smith Salley & Associates now owns 24,000 shares of the company's stock worth $41,000 after acquiring an additional 12,000 shares during the period. Finally, Stratos Wealth Partners LTD. acquired a new stake in shares of Ginkgo Bioworks during the 3rd quarter worth approximately $43,000. 78.63% of the stock is currently owned by institutional investors and hedge funds.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
